---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-038473"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:09:23.162249+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics closes $161.8M public offering of 19.7M shares at $8.74

## Summary
- Offered 17,162,472 shares plus 2,574,370 option shares exercised immediately.
- Net proceeds ~$161.8M after underwriting discounts and estimated expenses.
- Joint bookrunners: Leerink Partners, Citigroup, Guggenheim Securities.
- All shares sold by company; offering closed February 16, 2024.
- Proceeds will support clinical development of nomlabofusp (CTI-1601) and general corporate purposes.

## SEC filing metadata
- accession: 0001193125-24-038473
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312524038473/0001193125-24-038473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312524038473/d780024d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-038473
- JSON: https://secwatch.observer/filing/0001193125-24-038473.json
- Plain text: https://secwatch.observer/filing/0001193125-24-038473.txt

## Key facts
- Material Agreements
  Larimar Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein valued at approximately $161.8 million (effective 2024-02-14).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein
  - Value: approximately $161.8 million
  - Effective: 2024-02-14
  source text: On February 14, 2024, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 17,162,472 shares (the “ Shares ”) of the common stock, par value $0.001 per share (the “ Common Stock ”), of the Company at a public offering price of $8.74 per share, less the underwriting discounts and commissions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000119312524038473/0001193125-24-038473-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.